FAA Proposes Easing Medical Certification Rules for Pilots With Non-Insulin-Dependent Diabetes
核心洞察
The FAA has proposed removing non-insulin diabetes (搜索) medications from the list of specifically disqualifying conditions for pilot medical certification, allowing AMEs to issue certificates directly.
The change could let aviation medical examiners issue first-, second-, or third-class certificates in roughly 3,000 cases annually, with another 1,200 transitioning from Special Issuance.
The FAA estimates the proposal would save applicants between $39.7 million and $80.2 million in labor costs over five years, with no flight-safety impact identified.
The Federal Aviation Administration (搜索) (FAA) on Thursday proposed changing its medical certification rules to allow pilots whose diabetes (搜索) is controlled using non-insulin medications to potentially receive first-, second-, or third-class medical certificates without going through the agency's Special Issuance process. The proposed rule is scheduled for publication in the Federal Register on Friday.
Under current regulations, diabetes (搜索) that requires insulin or another hypoglycemic drug for control is considered a specifically disqualifying condition. Pilots using non-insulin medications can still qualify for a medical certificate, although an aviation medical examiner (AME) generally must defer the application to the FAA for Special Issuance review. The proposal would remove non-insulin medications from that provision and allow qualified applicants to be evaluated under the FAA's general medical standards.
Rationale for the Proposed Change
The FAA grounded its proposal in the substantial therapeutic advances made since the diabetes (搜索) standard was first written in 1959. "The availability of numerous new diabetes medication classes and other non-insulin treatments has substantially improved disease management," the FAA said in the proposed rule.
The agency noted that the diabetes (搜索) standard dates to 1959 and said advances in treatment have reduced severe complications including cardiovascular events and hypoglycemia. The proposed rule states that "diabetes is now more effectively controlled, resulting in a reduction in severe complications, including cardiovascular events, hypoglycemia, and other adverse outcomes."
Projected Workload and Cost Savings
The FAA estimates the change could allow AMEs to issue medical certificates at the time of examination in about 3,000 cases each year. Another 1,200 cases currently handled through Special Issuance could potentially transition to AME-managed certification.
Over five years, the agency estimates the change would save applicants between $39.7 million and $80.2 million in labor costs. "Processing all NIDDM cases via the SI process places a burden on applicants and FAA," the agency said. The FAA expects the proposal to reduce certification wait times and its own processing workload while shortening the process for pilots whose diabetes (搜索) is well controlled.
Safety Review
As part of the proposal, the FAA reviewed 51 fatal accidents from 2008 through 2025 involving pilots who were reported to be using non-insulin diabetes (搜索) medications. The agency determined that diabetes, related complications, or diabetes medication were unlikely to have contributed to 50 of those accidents. One case remains under investigation.
Scope and Limitations of the Proposal
The proposal would not change the requirements for pilots whose diabetes (搜索) is treated with insulin, who would continue to require Special Issuance authorization. Pilots using non-insulin treatments could also be denied or deferred on a case-by-case basis when the FAA or an AME determines the condition or treatment could interfere with the safe exercise of pilot privileges.
Comments will be accepted for 30 days following publication of the proposal.